title: Rheumatoid arthritis in 2012: Progress in RA genetics, pathology and therapy.
abstract: Developments in our knowledge of the aetiology and pathogenesis of rheumatoid arthritis continued apace in 2012, and several important new advances were reported in the therapy of this disease. Culminating in the approval of a new therapy in the USA, the year offered new insights for clinicians and fresh hope for patients.
authors.affiliation: Department of Medicine, Karolinska Institute, Karolinska University Hospital, Solna Building D1:00, Stockholm SE-17176, Sweden. ronald.van.vollenhoven@ki.se
authors.forename: Ronald F
authors.initials: RF
authors.lastname: van Vollenhoven
mesh_terms: D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology*; D019468:Disease Management; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006680:HLA Antigens / Q000235:genetics; D006801:Humans; D010880:Piperidines / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use
chemical_list: D004791:Enzyme Inhibitors; D006680:HLA Antigens; D010880:Piperidines; D011743:Pyrimidines; D011758:Pyrroles; C479163:tofacitinib; D011505:Protein-Tyrosine Kinases